This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Incyte's (INCY) Lymphoma Drug Obtains Positive CHMP Opinion
by Zacks Equity Research
Incyte (INCY) and MorphoSys (MOR) receive positive CHMP opinion for tafasitamab in combination with Revlimid for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
NVSNegative Net Change BMYNegative Net Change INCYNegative Net Change MORPositive Net Change
biotechs pharmaceuticals
Mirati's (MRTX) Adagrasib Gets Breakthrough Therapy Status
by Zacks Equity Research
Mirati (MRTX) is developing adagrasib as a potential treatment for patients suffering from non-small cell lung cancer with KRAS mutation. An NDA is expected to be filed in the second half of 2021.
MRKNegative Net Change LLYNegative Net Change QGENNegative Net Change MRTXPositive Net Change
biotechs
BioMarin's (BMRN) Vosoritide Gets CHMP Nod to Treat Dwarfism
by Zacks Equity Research
Biomarin Pharmaceutical (BMRN) receives positive recommendation from Europe's CHMP for vosoritide to treat achondroplasia in children.
BMRNNegative Net Change BAYRYNegative Net Change RGENNegative Net Change BNTXNegative Net Change
biotechs
Beyond Air (XAIR) is in Overbought Territory: What's Next?
by Zacks Equity Research
Beyond Air (XAIR) has moved higher as of late, but there could definitely be trouble on the horizon for this company
XAIRNegative Net Change
biotechs medical
Regeneron (REGN)/Sanofi's Libtayo Approved for Additional Indications
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi win EC approval for Libtayo for skin cancer and lung cancer.
REGNNegative Net Change SNYNegative Net Change MRKNegative Net Change BAYRYNegative Net Change
biotechs pharmaceuticals
Alnylam's (ALNY) NDA For Vutrisiran Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Alnylam's (ALNY) NDA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. A decision is due on Apr 14, 2022.
ALNYNegative Net Change RGENNegative Net Change TECHNegative Net Change TRVNNo Net Change
biotechs
Entera (ENTX) Up on Positive Results From Osteoporosis Drug
by Zacks Equity Research
Entera (ENTX) gains on positive results from a mid-stage study on its osteoporosis candidate at six months.
LLYNegative Net Change AMGNPositive Net Change RGENNegative Net Change ENTXPositive Net Change
biotechs medical
Editas (EDIT) Begins Enrollment in Kids Arm of Gene Drug Study
by Zacks Equity Research
Editas (EDIT) starts enrollment of the first pediatric cohort in the phase I/II BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10). Stock up.
ABBVNegative Net Change EDITPositive Net Change NTLANegative Net Change CRSPNegative Net Change
biotechs
Biotech Stock Roundup: BIIB's AD Drug Update, CVAC's Decline on Vaccine Data & More
by Zacks Equity Research
The biotech sector was in focus last week with pipeline updates from Biogen (BIIB) and CureVac (CVAC), among others.
BIIBNegative Net Change BMYNegative Net Change AVXLNegative Net Change SAVAPositive Net Change CVACNegative Net Change
biotechs medical
3D Systems (DDD) Joins CollPlant for Bioprinted Breast Tissue Matrix
by Zacks Equity Research
The collaborative efforts of 3D Systems (DDD) and CollPlant aim to eliminate the odds of adverse immune response in the human body induced by procedures using tissue derived from humans and animals.
UTHRNegative Net Change DDDNegative Net Change SIMONegative Net Change CLGNNegative Net Change
biotechs medical tech-stocks
Halozyme (HALO) Inks Collaboration Deal With Glaxo's HIV Unit
by Zacks Equity Research
Halozyme (HALO) and Glaxo's HIV company, ViiV Healthcare sign a collaboration agreement, which gives the latter exclusive right to Halozyme's ENHANZE technology to develop therapies targeting HIV
GSKNegative Net Change JNJNegative Net Change PFENegative Net Change HALOPositive Net Change
biotechs
Gilead (GILD) Veklury Data Positive in Hospitalized COVID Patients
by Zacks Equity Research
Gilead (GILD) announces positive data on Veklury in hospitalized patients with COVID-19 across three analyses of large retrospective real-world data sets.
REGNNegative Net Change GSKNegative Net Change GILDNegative Net Change VIRNegative Net Change
biotechs medical pharmaceuticals
Bristol Myers' (BMY) Onureg Gets European Commission Approval
by Zacks Equity Research
Bristol Myers (BMY) wins approval for acute myeloid leukemia drug, Onureg, in the European Union.
BMYNegative Net Change MRKNegative Net Change RGENNegative Net Change
biotechs pharmaceuticals
Here's Why Prothena (PRTA) Stock Is Up So Far This Month
by Zacks Equity Research
Prothena (PRTA) surges on the prospects of its Alzheimer's disease drug candidates, following Biogen???s AD drug approval.
BIIBNegative Net Change BMYNegative Net Change LLYNegative Net Change PRTANegative Net Change
biotechs medical pharmaceuticals
AMC FUD Runneth Over: Panic at the Casino!
by Kevin Cook
Should AMC be worth over 5X what Amazon just paid for MGM Studios?
AMDPositive Net Change NVDAPositive Net Change AMCNegative Net Change EDITPositive Net Change ARKKPositive Net Change
biotechs tech-stocks
Geron (GERN) Soars on Imetelstat Data for Myelofibrosis
by Zacks Equity Research
Geron (GERN) publishes data from the phase II IMbark study evaluating its lead pipeline candidate, imetelstat, for treating relapsed/refractory myelofibrosis. Stock rises.
GERNPositive Net Change RGENNegative Net Change TECHNegative Net Change TRVNNo Net Change
biotechs
Will Emergence of COVID-19 Delta Variant Aid Vaccine Makers?
by Zacks Equity Research
The new variant of COVID-19 virus, delta, is increasing the risk of infections across the globe. This will likely lead to higher demand for COVID-19 vaccines and therapeutics.
JNJNegative Net Change PFENegative Net Change MRNANegative Net Change BNTXNegative Net Change
biotechs pharmaceuticals
Bristol-Myers (BMY) Partners Eisai for Antibody Drug Conjugate
by Zacks Equity Research
Bristol-Myers (BMY) teams up with Eisai to co develop MORAb-202, an antibody drug conjugate (ADC).
BMYNegative Net Change MRKNegative Net Change RGENNegative Net Change
biotechs pharmaceuticals
Biogen (BIIB) Initiates Late-Stage Study on Lupus Candidate
by Zacks Equity Research
Biogen (BIIB) is developing its monoclonal antibody candidate, BIIB059, as a potential treatment for active systemic lupus erythematosus.
BIIBNegative Net Change RGENNegative Net Change BLPHPositive Net Change BNTXNegative Net Change
biotechs
Gilead (GILD) Inks Deal to Develop Allogeneic Cell Therapies
by Zacks Equity Research
Gilead's (GILD) wholly owned subsidiary Kite signs partnership deal with Shoreline Biosciences to develop novel cell therapies for cancer.
GILDNegative Net Change RGENNegative Net Change TECHNegative Net Change KMDANegative Net Change
biotechs
Biogen's Alzheimer's Drug Approval Puts Biotech ETFs in Spotlight
by Sweta Jaiswal, FRM
The FDA's approval of the first new drug to treat Alzheimer's disease in about 20 years has attracted investors' attention toward the biotech sector while sparking new controversies.
BIIBNegative Net Change IBBNegative Net Change XBINegative Net Change BBHNegative Net Change FBTNegative Net Change BTECPositive Net Change
biotechs etfs
Blueprint Medicines (BPMC) Gets FDA Nod for Ayvakyt in SM
by Zacks Equity Research
The FDA approves Blueprint Medicines' (BPMC) lead drug, Ayvakit, for treating adult patients with advanced systemic mastocytosis.
RGENNegative Net Change TECHNegative Net Change KMDANegative Net Change
biotechs
CureVac (CVAC) Plummets on Disappointing COVID-19 Vaccine Data
by Zacks Equity Research
CureVac (CVAC) down as it announces that its first-generation COVID-19 vaccine candidate, CVnCoV, did not meet the prespecified statistical success criteria in a phase IIb/III study.
GSKNegative Net Change PFENegative Net Change BAYRYNegative Net Change CVACNegative Net Change
biotechs
Biogen (BIIB) Ends Development of Anti-Tau Alzheimer's Drug
by Zacks Equity Research
Biogen (BIIB) ends development of investigational anti-tau antibody, gosuranemab for treating Alzheimer's disease after the phase II TANGO study showed no benefit to patients.
NVSNegative Net Change BIIBNegative Net Change RHHBYNegative Net Change AMGNPositive Net Change
biotechs
Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal
by Zacks Equity Research
Aprea (APRE) announces that treatment with a combination regimen of its pipeline candidate, eprenetapopt, achieves 37% complete response rate in acute myeloid leukemia patients.
RHHBYNegative Net Change ABBVNegative Net Change APRENegative Net Change BNTXNegative Net Change
biotechs